Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review

Overview

Journal Life (Basel)

Specialty Biology

Date 2024 Apr 27

PMID 38672794

Authors

Evdokia Mandala

Kyranna Lafara

Dimitrios Kokkinovasilis

Ioannis Kalafatis

Vasiliki Koukoulitsa

Eirini Katodritou

Christos Lafaras

Affiliations

Soon will be listed here.

Abstract

Applied cardio-oncology in hematological malignancies refers to the integration of cardiovascular care and management for patients with blood cancer, particularly leukemia, lymphoma, and multiple myeloma. Hematological cancer therapy-related cardiotoxicity deals with the most common cardiovascular complications of conventional chemotherapy, targeted therapy, immunotherapy, chimeric antigen receptor T (CAR-T) cell and tumor-infiltrating lymphocyte therapies, bispecific antibodies, and hematopoietic stem cell transplantation. This narrative review focuses on hematological cancer-therapy-related cardiotoxicity's definition, risk stratification, multimodality imaging, and use of cardiac biomarkers to detect clinical and/or subclinical myocardial dysfunction and electrical instability. Moreover, the most common cardiotoxic profiles of the main drugs and/or therapeutic interventions in patients with hematological malignancies are described thoroughly.

Citing Articles

Cardiovascular Risk Factors Predicting Cardiovascular and Cancer Deaths in a Middle-Aged Population Followed-Up for 61 Years until Extinction.

Menotti A, Puddu P, Piras P J Cardiovasc Dev Dis. 2024; 11(8).

PMID: 39195148 PMC: 11354922. DOI: 10.3390/jcdd11080240.

References

Totzeck M, Aide N, Bauersachs J, Bucerius J, Georgoulias P, Herrmann K . Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM). Eur J Nucl Med Mol Imaging. 2022; 50(3):792-812. PMC: 9852191. DOI: 10.1007/s00259-022-05991-7. View

Iqubal A, Wasim M, Ashraf M, Najmi A, Syed M, Ali J . Natural Bioactive as a Potential Therapeutic Approach for the Management of Cyclophosphamide-induced Cardiotoxicity. Curr Top Med Chem. 2021; 21(29):2647-2670. DOI: 10.2174/1568026621666210813112935. View

Siaravas K, Katsouras C, Sioka C . Radiation Treatment Mechanisms of Cardiotoxicity: A Systematic Review. Int J Mol Sci. 2023; 24(7). PMC: 10094086. DOI: 10.3390/ijms24076272. View

Ratosa I, Ivanetic Pantar M . Cardiotoxicity of mediastinal radiotherapy. Rep Pract Oncol Radiother. 2019; 24(6):629-643. PMC: 6838493. DOI: 10.1016/j.rpor.2019.09.002. View

Bock A, Nowakowski G, Wang Y . Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. Curr Treat Options Oncol. 2022; 23(2):155-170. DOI: 10.1007/s11864-021-00925-1. View

Cardinale D, Zaninotto M, Cipolla C, Passino C, Plebani M, Clerico A . Cardiotoxic effects and myocardial injury: the search for a more precise definition of drug cardiotoxicity. Clin Chem Lab Med. 2020; 59(1):51-57. DOI: 10.1515/cclm-2020-0566. View

Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A . Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021; 42(16):1554-1568. PMC: 8060056. DOI: 10.1093/eurheartj/ehab072. View

Tuzovic M, Mead M, Young P, Schiller G, Yang E . Cardiac Complications in the Adult Bone Marrow Transplant Patient. Curr Oncol Rep. 2019; 21(3):28. DOI: 10.1007/s11912-019-0774-6. View

Madonna R . Multi-Target Drugs for Blood Cancer in the Elderly: Implications of Damage and Repair in the Cardiovascular Toxicity. Front Physiol. 2021; 12:792751. PMC: 8688949. DOI: 10.3389/fphys.2021.792751. View

10.

Gent D, Rebecca D . The 2022 European Society of Cardiology Cardio-oncology Guidelines in Focus. Eur Cardiol. 2023; 18:e16. PMC: 10316349. DOI: 10.15420/ecr.2022.63. View

11.

Schmittlutz K, Marks R . Current treatment options for aggressive non-Hodgkin lymphoma in elderly and frail patients: practical considerations for the hematologist. Ther Adv Hematol. 2021; 12:2040620721996484. PMC: 7940714. DOI: 10.1177/2040620721996484. View

12.

Kelly J, Babich J . PET Tracers for Imaging Cardiac Function in Cardio-oncology. Curr Cardiol Rep. 2022; 24(3):247-260. PMC: 8934332. DOI: 10.1007/s11886-022-01641-4. View

13.

Pudil R, Mueller C, Celutkiene J, Henriksen P, Lenihan D, Dent S . Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020; 22(11):1966-1983. DOI: 10.1002/ejhf.2017. View

14.

Palladini G, Milani P . Diagnosis and Treatment of AL Amyloidosis. Drugs. 2023; 83(3):203-216. DOI: 10.1007/s40265-022-01830-z. View

15.

Printezi M, Yousif L, Kamphuis J, van Laake L, Cramer M, Hobbelink M . LVEF by Multigated Acquisition Scan Compared to Other Imaging Modalities in Cardio-Oncology: a Systematic Review. Curr Heart Fail Rep. 2022; 19(3):136-145. PMC: 9177497. DOI: 10.1007/s11897-022-00544-3. View

16.

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni C, Veglia F . Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; 131(22):1981-8. DOI: 10.1161/CIRCULATIONAHA.114.013777. View

17.

Haslauer T, Greil R, Zaborsky N, Geisberger R . CAR T-Cell Therapy in Hematological Malignancies. Int J Mol Sci. 2021; 22(16). PMC: 8396650. DOI: 10.3390/ijms22168996. View

18.

Cardinale D, Iacopo F, Cipolla C . Cardiotoxicity of Anthracyclines. Front Cardiovasc Med. 2020; 7:26. PMC: 7093379. DOI: 10.3389/fcvm.2020.00026. View

19.

Bansal N, Joshi C, Adams M, Hutchins K, Ray A, Lipshultz S . Cardiotoxicity in pediatric lymphoma survivors. Expert Rev Cardiovasc Ther. 2021; 19(11):957-974. DOI: 10.1080/14779072.2021.2013811. View

20.

Lyon A, Lopez-Fernandez T, Couch L, Asteggiano R, Aznar M, Bergler-Klein J . 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022; 23(10):e333-e465. DOI: 10.1093/ehjci/jeac106. View